Nevirapine (Viramune): Research
- Longer Use of Nevirapine Stops HIV in Babies (March 8, 2013)
From MedPage Today
- Nevirapine-Containing ART Does Not Reduce Combined Oral Contraceptive Effectiveness (January/February 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Lipid Profile in Children in PREDICT: Immediate Versus Deferred Nevirapine-Based ART (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Adding Nevirapine to HIV Regimen Halves Newborn Transmission Rate (June 20, 2012)
Findings from NIH network support shift in prevention guidelines.
From U.S. National Institutes of Health
On TheBodyPRO.com
- Kaletra Superior to Viramune in HIV-Positive Infants, U.S. Study Finds (November 3, 2010)
From National Institute of Allergy and Infectious Diseases
On TheBodyPRO.com
- NEJM PMTCT Studies (October 15, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Study Findings on Nevirapine Support WHO HIV Treatment Guideline Changes (October 14, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Once-Daily "Extended" Formulation of Nevirapine Holds Up Well in 48-Week Study Results (September 15, 2010)
In The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Study Shows Nevirapine a New Treatment Option for HIV-Positive Infants (September 8, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Once-Daily Extended-Release Nevirapine Works as Well as Twice-Daily Formulation (July 23, 2010)
From aidsmap.com
- Viramune Boosts Hep C Treatment Efficacy in People With HIV (July 20, 2010)
From AIDSmeds.com
- PLoS Medicine Study Compares Effectiveness of NVP in Women Previously Exposed to Drug (February 19, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Nevirapine Matches Atazanavir/Ritonavir in 48-Week Study (July 29, 2009)
Nevirapine has equivalent efficacy to atazanavir/ritonavir when combined with tenofovir and emtricitabine in treatment-naive patients, results from the ARTEN study show.
From aidsmap.com
- Nevirapine Sports Better Lipid Profile Than Atazanavir, Study Suggests (July 20, 2009)
Patients taking nevirapine may have a lower risk of developing cardiovascular disease than those taking ritonavir-boosted atazanavir, according to a 569-patient study by European researchers. The study found that although nevirapine's efficacy was non-inferior to that of atazanavir, nevirapine appeared to have a more favorable lipid profile.
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (December 2008)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
On TheBodyPRO.com
- High LDL Cholesterol Levels May Drop by Switching Sustiva to Viramune, Study Says (June 12, 2007)
From AIDSmeds.com
- Nevirapine-Associated Toxicity Less Frequent in Non-Naive Patients (August 17, 2006)
In XVI International AIDS Conference
On TheBodyPRO.com
- Hepatotoxicity in IDUs and Non-IDUs Receiving Nevirapine-Based HAART (August 16, 2006)
In XVI International AIDS Conference
On TheBodyPRO.com
- Nevirapine Resistance May Persist in Some Pregnant Women, Study Finds (May 3, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- In Uganda, Three-NRTI Regimen Including Abacavir Is Better Tolerated Than Nevirapine-Based Regimen (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
On TheBodyPRO.com
|
Advertisement
|
Email
Glossary
